

D₂
26. (Amended) ~~[The]~~ A single DNA [of claim 1 further] comprising a nucleic acid sequence coding for cystic fibrosis transmembrane conductance regulator comprising the nucleic acid sequence set forth in Table 1 having at least one intron located within the cystic fibrosis transmembrane conductance regulator coding region.

D₃
36. (Amended) A low copy number vector comprising DNA [encoding cystic fibrosis transmembrane conductance regulator] which encodes the amino acid sequence of cystic fibrosis transmembrane conductance regulator set forth in Table 1.

D₄
39. (Amended) The vector of claim [38] ~~36~~ comprising the vector pkk-CFTR3.

40. (Amended) The vector of claim 36 [further comprising a stabilizing element] wherein the DNA is stabilized against cellular recombination.

D₅
54. (Amended) A therapeutic composition comprising a carrier comprising [the vector of claim 51] a vector comprising the DNA of claim 1 which after administration, augments the in vivo production or activity of cystic fibrosis transmembrane conductance regulator.

55. (Amended) A host cell comprising the DNA of claim 1, the DNA of claim ~~26~~[36], the DNA of claim ~~36~~[47, the DNA of claim 48] or the DNA of claim 50.

D₆
62. (Amended) A host cell comprising a vector containing the DNA of claim [25] 1, the DNA of claim 26, the [vector] DNA of claim [38] ~~36~~ or the [vector of claim 42] DNA of claim 50.

Do not allow
should not
have been
examined as
amended
BDS 4/14